Filing Flows › Health Care › RxSight (RXST)
RxSight (RXST) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · RxSight (RXST) Q3 2026 earnings results →
Q3 2026 Revenue down 19% year over year to $24.6M · 66¢ of every $1 of revenue lost · operating margin -75.3%
RxSight made $24.6M in Q3 2026 (-19% Y/Y): Rxlal $22.8M, Service Warranty Service Contracts and Accessories $1.4M, LDD $427K. Operating margin -75.3%, net loss $16.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $24.6M in Q3 2026, down 19% year over year and down 27% from the previous quarter. Rxlal was the largest line at 93% of revenue. Rxlal lost $2.9M year over year (down 11%), 51% of the total change.
Operating costs exceeded revenue by $18.5M, an operating margin of -75.3%. The quarter ended with a net loss of $16.2M, wider than the previous quarter's $12.1M loss.
Operating cash flow was $45.2M. Non-cash charges added back $929K of depreciation and amortization and $7.6M of share-based compensation. Working capital and other items added $52.9M. Capital expenditures of $1.2M left free cash flow of $44.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $24.6M | -19% | -75.3% | −$16.2M | $45.2M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $33.7M | +0.3% | -40.8% | −$12.1M | −$9.5M |
| Q1 2026 | 10-Q | May 6, 2026 | $30.9M | -18% | -57.7% | −$15.9M | −$10.9M |
| Q4 2025 | 10-K | Feb 25, 2026 | $32.6M | -19% | -34.8% | −$9.2M | −$1.1M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $30.3M | -14% | -40.1% | −$9.8M | −$1.2M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $33.6M | -4% | -41.6% | −$11.8M | −$4.4M |
| Q1 2025 | 10-Q | May 7, 2025 | $37.9M | +28% | -28.2% | −$8.2M | −$8.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About RxSight
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight ® Light Adjustable Lens system (“RxSight system”) is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens ® (LAL ® /LAL+ ® , collectively the “LAL”), RxSight Light Delivery Device (“LDD™”) and related accessories. The LAL is a premium intraocular lens (“IOL”) made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet (“UV”) light patterns generated by the LDD.
In its own words, from its 10-K, filed Feb 25, 2026.
RxSight against its Ophthalmic Goods peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -19% against the peers' median +2%. Operating margin: -75.3% against the peers' median 4.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RXST RxSight | Q3 2026 | $24.6M | -19% | -75.3% |
| BLCO Bausch & Lomb | Q3 2026 | $1.4B | +7% | 11.3% |
| COO Cooper Companies | Q3 FY26 | $1.1B | +0.6% | 20.8% |
| EYE National Vision Holdings | Q2 2026 | $499M | +2% | 4.3% |
| WRBY Warby Parker | Q3 2026 | $245M | +10% | 1.5% |
| STAA Staar Surgical | Q3 2026 | $83.4M | -12% | 6.5% |
| LUCYW Innovative Eyewear | Q2 2026 | $1.0M | +74% | -165.3% |
Source: RxSight 10-Q on SEC EDGAR · CIK 1111485 · Ophthalmic Goods
13F: who owns RXST and who is buying
More on RXST
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results